<DOC>
	<DOCNO>NCT00381693</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , azacitidine , work different way stop growth abnormal cell , either kill cell stop dividing . PURPOSE : This phase II trial study well azacitidine work treat patient myelofibrosis .</brief_summary>
	<brief_title>Azacitidine Treating Patients With Myelofibrosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy azacitidine patient myelofibrosis ( MF ) myeloid metaplasia . - Evaluate safety azacitidine patient . Secondary - Evaluate pertinent biologic characteristic MF therapy azacitidine . - Assess effect study treatment constitutional symptom patient . - Estimate time event distribution overall survival progression . OUTLINE : Patients receive azacitidine subcutaneously daily day 1-5 . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm myelofibrosis myeloid metaplasia ( MMM ) , include follow subtypes : Agnogenic myeloid metaplasia Postpolycythemic myeloid metaplasia Postthrombocythemic myeloid metaplasia Evaluable symptomatic disease , define 1 following : Anemia ( hemoglobin &lt; 10 g/dL erythrocyte transfusiondependent , require 1 transfusion ≤ 8 week ) Treatment required* symptomatic palpable splenomegaly ( palpable hepatomegaly acceptable previously splenectomized ) NOTE : *Subjective painful enough mandate intervention Absence ( 9 ; 22 ) fluorescent situ hybridization ( FISH ) standard cytogenetics ( peripheral blood marrow ) Previous demonstration lack translocation ( point ) sufficient No advance malignant hepatic tumor PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 50,000/mm³ Creatinine ≤ 2.0 mg/dL Total bilirubin ≤ 2.0 mg/dL OR direct bilirubin ≤ 2.0 mg/dL total bilirubin elevate ( unless attribute underlying disease ) AST ALT ≤ 2 time upper limit normal ( unless clinically attribute hepatic extramedullary hematopoiesis ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No baseline peripheral autonomic neuropathy ≥ grade 2 No condition , include presence laboratory abnormality , would preclude study compliance No hypersensitivity mannitol azacitidine Not incarcerate municipality ( i.e. , county , state , federal prison ) PRIOR CONCURRENT THERAPY : At least 14 day since prior chemotherapy , include interferon alfa , anagrelide , myelosuppressive agent At least 14 day since prior systemic corticosteroid At least 14 day since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>primary myelofibrosis</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>secondary myelofibrosis</keyword>
</DOC>